Compare CVS Health Corp (CVS) vs Enovix Corporation (ENVX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Enovix Corporation — how do they compare? CVS Health Corp trades at $86.82 (market cap $112.49B), while Enovix Corporation trades at $2.52 (market cap $561.79M). The key difference: CVS Health Corp is far larger — about 200.2× Enovix Corporation's market cap, and CVS Health Corp pays a 3.02% dividend while Enovix Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Enovix Corporation for 11 Days on average.
| CVS | ENVX | |
|---|---|---|
Market Cap | $112.49B | $561.79M |
Volume | 8,467,392 | 5,898,906 |
Sector | Health | Industrials |
52-Week High | $110.60 | $13.19 |
52-Week Low | $70.08 | $2.50 |
Typical Hold Time | 83 Days | 11 Days |
Enterprise Value | $174.83B | $623.49M |
Dividend Yield | 3.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.95, up 1.76% with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 26% upside. Recent quarterly earnings consistently beat expectations, with Q2 2026 EPS of $2.58 surpassing the $1.85 estimate. Revenue growth remains solid at $402.07 billion for 2025, though net margins compressed to 1.18%. Technical indicators show a bullish overall signal with support at $87 and resistance at $89.
The outlook remains positive given CVS's dominant market position and Medicare expansion plans, but investors face risks from reimbursement pressures and ongoing legal investigations. Earnings growth and successful execution of healthcare services integration represent the primary catalysts for continued stock appreciation.
ENVX trades at $2.55, down 5.56% today, reflecting ongoing investor concerns despite recent earnings beats. The stock shows bearish technical signals with negative moving averages and oscillators. Fundamentally, the company continues to burn cash with a net income margin of -473.89% in 2026, though revenue growth remains positive at 32% year-over-year. Recent CEO transition and strategic focus on defense battery manufacturing create uncertainty about execution.
The outlook remains challenging with significant cash burn and negative profitability, though analyst consensus is bullish with a $10.75 price target representing 321% upside. Key risks include execution challenges, high cash consumption, and competitive pressures in the battery sector. The company's $552 million cash position provides runway but requires successful commercialization to justify valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →
